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INTRODUCTION 
The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of 
a group of metabolic abnormalities that confer increased risk of cardiovascular 
disease (CVD) and diabetes mellitus. Evolution of the criteria for the metabolic 
syndrome since the original definition by the World Health Organization 
(WHO)  in 1998 reflects growing clinical evidence and analysis by a variety of 
consensus conferences and professional organizations that led to the increasing 
understanding of this syndrome. The major features of the metabolic syndrome 
include central obesity, hyper triglyceridemia, low levels of high-density 
lipoprotein (HDL) cholesterol, hyperglycemia, and hypertension. 
 
RISK FACTORS 
Overweight/Obesity 
Although the metabolic syndrome was first described in the early twentieth 
century, the worldwide overweight/obesity epidemic has recently been the force 
that driving its increasing recognition and treatment. Central adiposity is a key 
feature of the syndrome, and the syndrome’s prevalence reflects the strong 
relationship between waist circumference and increasing adiposity and 
increasing weight. However, despite the importance of obesity, patients who 
are of normal weight may also be insulin resistant and may have the metabolic 
syndrome and associated morbidity. 
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Sedentary Lifestyle 
Physical inactivity is a predictor of CVD events and the related increased risk 
of death. Many components of the metabolic syndrome are associated with a 
sedentary lifestyle, including increased adipose tissue (predominantly central) 
accumulation, reduced HDL cholesterol level, and increased triglycerides, 
blood pressure, and glucose in genetically susceptible population. Compared 
with individuals who watch television or videos or use the computer <1 h daily, 
those who do so for >4 h daily have a twofold increased risk of the metabolic 
syndrome and related risk of death. 
Aging 
The metabolic syndrome affects nearly 50% of the U.S. population older than 
age 50 years and at >60 years of age women are more often affected than men. 
The age dependency of the syndrome’s prevalence is seen in most populations 
around the world in most of the countries. 
Diabetes Mellitus 
Diabetes mellitus is included in both the national cholesterol educational 
program and the harmonizing definitions of the metabolic syndrome. It is 
estimated that the great majority (~75%) of the patients with type 2 diabetes or 
the impaired glucose tolerance have the metabolic syndrome. The presence of 
the metabolic syndrome in these populations around the world relates to a 
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higher prevalence of cardiovascular disease than in patients who have type 2 
diabetes or impaired glucose tolerance but do not have the metabolic syndrome. 
Cardiovascular Disease 
Individuals with the metabolic syndrome are twice as likely to die of 
cardiovascular disease as those who do not have the syndrome,and their risk of 
an acute myocardial infarction or stroke is threefold higher than those who do 
not have the syndrome. The approximate prevalence of the metabolic syndrome 
among patients with coronary heart disease (CHD) is 50%, with a prevalence of 
~35% among patients with premature coronary artery disease (before or at age 
45) and a particularly high prevalence among women than men. With 
appropriate cardiac rehabilitation and changes in lifestyle (e.g., nutrition, 
physical activity, weight reduction, and—in some cases—pharmacologic 
therapy, appropriate diet), the prevalence of the syndrome can be reduced to a 
satisfactory level. 
Lipodystrophy 
Lipodystrophic disorders in general are associated with the metabolic 
syndrome. Both genetic form of lipodystrophy (e.g., Berardinelli- Seip 
congenital lipodystrophy, Dunnigan familial partial lipodystrophy) and 
acquired form of  lipodystrophy (e.g., HIV-related lipodystrophy in higher 
prevalence of cardiovascular disease than in patients who have type 2 diabetes 
mellitus or impaired glucose tolerance but do not have this syndrome. 
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Cardiovascular Disease  
Individuals with the metabolic syndrome are twice as likely to die of the 
cardiovascular disease as those who do not, and their risk of an acute 
myocardial infarction or stroke is threefold higher the others. The approximate 
prevalence of the metabolic syndrome among these patients with coronary heart 
disease (CHD) is 50%, with a  high prevalence of ~35% among patients with 
premature coronary artery disease (before or at age 45) and a particularly high 
prevalence among women. With appropriate cardiac rehabilitation and changes 
in lifestyle (e.g., diet control, nutrition, physical activity, weight reduction, 
and—in some cases—pharmacologic therapy), the prevalence of the syndrome 
can be reduced 
 
ETIOLOGY 
Insulin Resistance 
The most accepted and unifying hypothesis to describe the pathophysiology of 
the metabolic syndrome is insulin resistance, which is caused by an 
incompletely understood defect in insulin action and its receptors biology. The 
onset of insulin resistance is heralded by postprandial hyperinsulinemia, which 
is followed by fasting hyperinsulinemia and ultimately by hyperglycemia then 
leading to overt diabetes mellitus. An early major contributor to the 
development of insulin resistance is an overabundance of circulating  free fatty 
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acids . Plasma albumin-bound free fatty acids are derived predominantly from 
adipose-tissue triglyceride stores released by intracellular lipolytic enzymes in 
the body. Fatty acids are also derived from the lipolysis of triglyceride rich 
lipoproteins in tissues by lipoprotein lipase. Insulin mediates both antilipolysis 
and the stimulation of lipoprotein lipase in adipose tissue. Of note, the 
inhibition of lipolysis in adipose tissue in the body is the most sensitive 
pathway of insulin action. Thus, when insulin resistance develops in the body, 
increased lipolysis produces more fatty acids synthesis, which further decrease 
the antilipolytic effect of insulin. Excessive fatty acids enhance the substrate 
availability and create insulin resistance by modifying downstream signaling 
pathways within the cell. Fatty acids impair insulin-mediated glucose uptake 
and accumulate as triglycerides in both skeletal and cardiac muscle, whereas 
increased glucose production and triglyceride accumulation take place within 
the liver. Leptin resistance has also been raised as a possible pathophysiologic 
mechanism to explain the metabolic syndrome. Physiologically, leptin reduces 
the appetite, promotes energy expenditure, and enhances the insulin sensitivity. 
In addition, leptin may regulate the cardiac and vascular function through a 
nitric oxide–dependent mechanism that happens in the body. However, when 
obesity develops, hyperleptinemia ensues, with evidence of leptin resistance in 
the brain and all other tissues resulting in inflammation, insulin resistance, 
hyperlipidemia, and a plethora of cardiovascular disorders, such as 
hypertension, atherosclerosis, CHD, and heart failure that contributes to its 
morbidity. The oxidative stress hypothesis provides a unifying theory for aging 
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and the predisposition to the metabolic syndrome. In studies of insulin resistant 
individuals with  the obesity or type 2 diabetes, the offspring of patients with 
type 2 diabetes, and the elderly,  have a defect in mitochondrial oxidative 
phosphorylation that leads to the accumulation of triglycerides and related lipid 
molecules in muscle has been identified.  
Recently, the gut microbiome has emerged as an important contributor to the 
development of the obesity and related metabolic disorders, including the 
metabolic syndrome. Although the mechanism remain uncertain, interaction 
among genetic predisposition, diet, and the intestinal flora is very important. 
Increased Waist Circumference  
Waist circumference is an important component of the most recent and 
frequently applied diagnostic criteria for the metabolic syndrome . However, 
measuring the waist circumference does not reliably distinguish increases in 
subcutaneous adipose tissue from those in visceral fat; this distinction requires 
imaging studies like CT or MRI. With increases in visceral adipose tissue, 
adipose tissue–derived free fatty acids are directed to the liver. In contrast, 
increases in abdominal subcutaneous fat release lipolytic  products into the 
systemic circulation and avert more direct effects on hepatic metabolism. 
Relative increases in visceral versus suncutaneous adipose tissue with 
increasing waist circumference in Asians and Asian Indians may explain the 
greater prevalence of the  metabolic syndrome in those populations than in 
African-American men, in whom SC fat  predominates than the visceral fat. It 
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is also possible that the visceral fat is a marker for—but not the source of— the 
excess postprandial free fatty acids in obesity. 
 
Dyslipidemia. 
In general, free fatty acid flux to the liver from the blood stream is associated 
with increased production of ApoB-containing,triglyceride-rich, very low-
density lipoproteins (VLDLs). The effect of insulin on this process is complex, 
but the hypertriglyceridemia is an excellent marker of the insulin-resistant 
condition. Not only is the  hypertriglyceridemia a feature of the metabolic 
syndrome, but patients with the metabolic syndrome have elevated levels of 
ApoCIII carried on VLDLs and the other lipoproteins. This increase in ApoCIII 
is inhibitory to the lipoprotein lipase, further contributing to 
hypertriglyceridemia and also associated with more atherosclerotic 
cardiovascular disease. The other major lipoprotein disturbance in the 
metabolic syndrome is a reduction in the HDL cholesterol. This reduction is a 
consequence of changes in HDL composition and metabolism. In the presence 
of hypertriglyceridemia, a decrease in the cholesterol content of HDL is a 
consequence of reduced cholesteryl ester content of the lipoprotein core in 
combination with cholesteryl ester transfer protein– mediated alterations in 
triglyceride that make the particle small and dense. This change in lipoprotein  
composition also results in the increased clearance of HDL from the circulation. 
These changes in HDL have a relationship to the insulin resistance that is 
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probably indirect, occurring in concert with the changes in triglyceride-rich 
lipoprotein metabolism. In addition to HDLs, low-density lipoproteins(LDLs) 
are modified in composition in the metabolic syndrome. With fasting serum 
triglycerides at >2.0 mM (~180 mg/dL), there is almost always a predominance  
small, dense LDLs, which are thought to be more atherogenic than other form 
of lipoproteins,although their association with hypertriglyceridemia and low 
HDLs make their independent contribution to cardiovascular disease events 
difficult to assess. Individuals with hypertriglyceridemia often have increases in 
cholesterol content of both VLDL1 and VLDL2 subfractions and in LDL 
particle number. Both of these lipoprotein changes may contribute to 
atherogenic risk in patients with the metabolic syndrome. 
 
Glucose Intolerance:  
 Defects in insulin action in the metabolic syndrome lead to the impaired 
suppression of glucose production by the liver and kidney and reduced glucose 
uptake and metabolism in insulin-sensitive tissues—i.e., muscle and adipose 
tissue. The relationship between impaired fasting glucose or impaired glucose 
tolerance and insulin resistance is well supported by studies of humans, 
nonhuman primates, and rodents. To compensate for defects in insulin action, 
insulin secretion and/or clearance must be modified so that the euglycemia is 
sustained. Ultimately, this compensatory mechanism fails, usually because of 
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defects in insulin secretion, resulting in progression from impaired fasting 
glucose and/ or impaired glucose tolerance to overt diabetes mellitus. 
Hypertension 
The relationship between insulin resistance and hypertension is well 
established. Paradoxically, under normal physiologic conditions, insulin is a 
vasodilator with secondary effects on sodium reabsorption in the renal system. 
However, in the setting of insulin resistance, the vasodilatory effect of insulin is 
lost but the renal effect on the  sodium reabsorption is preserved. Sodium 
reabsorption is increased in the whites with  metabolic syndrome but not in the 
Africans or Asians. Insulin also increases the activity of the sympathetic 
nervous system, an effect that may be preserved in the setting of the  insulin 
resistance. Insulin resistance is characterized by the  pathway specific 
impairment in phosphatidylinositol-3-kinase signaling (PI3). In the 
endothelium, this impairment may cause an imbalance between the production 
of nitric oxide and the secretion of endothelin 1, with a consequent decrease in 
blood flow. Although these mechanisms are provocative, the evaluation of 
insulin action by measurement of fasting insulin levels or by the homeostasis 
model assessment shows that the insulin resistance contributes only partially to 
the increased prevalence of hypertension in the metabolic syndrome. Another 
possible mechanism underlying hypertension in the metabolic syndrome is the 
vasoactive role of perivascular adipose tissue. Reactive oxygen species released 
by NADPH oxidase impair endothelial function and result in local 
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vasoconstriction. Other paracrine effects could be mediated by theleptin or 
other proinflammatory cytokines released from adipose tissue, such as tumor 
necrosis factor alpha. Another consequence of insulin resistance is 
hyperuricemia and is commonly observed  in the people with metabolic 
syndrome. There is growing evidence not only that the uric acid is associated 
with hypertension but also that reduction of uric acid normalizes blood pressure 
in hyperuricemic adolescents with the hypertension. The mechanism appears to 
be related to an adverse effect of uric acid on nitric acid synthase in the macula 
densa of the renal tubules in the kidney and its  stimulation of the renin-
angiotensin aldosterone system. 
 
Proinflammatory Cytokines: 
The increases in proinflammatory cytokines—including the interleukins 1, 6, 
and 18; resistin; tumor necrosis factor alpha; and the systemic biomarker C-
reactive protein—reflect overproduction by the expanded adipose tissue mass. 
Adipose tissue–derived macrophages may be the primary source of the 
proinflammatory cytokines locally and in the systemic circulation. It remains 
unclear, however, how much of the insulin resistance is caused by the paracrine 
effects of these cytokines and how much by the endocrine effects are unknown. 
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Adiponectin 
Adiponectin is an anti-inflammatory cytokine produced exclusively by the  
adipocytes. Adiponectin enhances the insulin sensitivity and inhibits many 
steps in the inflammatory process. In the liver, the adiponectin inhibits the 
expression of gluconeogenic enzymes and the rate of glucose production. In 
muscle, adiponectin increases glucose transport and enhances fatty acid 
oxidation, partially through the activation of AMP kinase. Adiponectin levels 
are reduced in the metabolic syndrome. The relative contributions of the 
adiponectin deficiency and overabundance of the proinflammatory cytokines 
are unclear. 
 
CLINICAL FEATURES 
Symptoms and Signs 
The metabolic syndrome typically is not associated with the symptoms. On 
physical examination, waist circumference may be increased and the  blood 
pressure is elevated. The presence of either or both of these signs should 
prompt the clinician to search for other biochemical abnormalities that may be 
associated with the metabolic syndrome. Less frequently, lipoatrophy or 
acanthosis nigricans, xanthomas are found on the examination. Because these 
physical findings characteristically are associated with severe insulin resistance, 
other components of the metabolic syndrome should be expected. 
  
- 13 - 
 
 
ACTION OF ADIPONECTIN 
 
 
  
- 14 - 
 
 Associated Diseases  
  CARDIOVASCULAR DISEASE 
 The relative risk for the  new onset CVD in patients with the metabolic 
syndrome who do not have diabetes averages 1.5–3 fold risk. However, an 8-
year follow-up of middle aged  participants in the Framingham   offspring 
Study documented that the population-attributable CVD risk in the metabolic 
syndrome was 34% among men and only 16% among women in the study. In 
the same study, both the metabolic syndrome and diabetes predicted ischemic 
stroke, with greater risk among patients with the metabolic syndrome than 
among those with diabetes alone (19% vs. 7%) and a particularly large 
difference among the women (27% vs. 5%). Patients with the metabolic 
syndrome are also at increased risk for the peripheral vascular disease. overall, 
the risk for type 2 diabetes among patients with the metabolic syndrome is 
increased three- to fivefold than others. In the Framingham Offspring Study’s 
8-year follow-up of middle-aged participants, the population-attributable risk 
for developing type 2 diabetes was 62% among men and 47% among the 
women. 
Other Associated Conditions 
In addition to the features specifically associated with the metabolic syndrome, 
other metabolic alterations accompany the  insulin resistance. Those alterations 
include increases in the ApoB and ApoCIII, uric acid level , prothrombotic 
factors (fibrinogen, plasminogen activator inhibitor 1), serum viscosity, 
asymmetric dimethylarginine, homocysteine, white blood cell count, 
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proinflammatory cytokines, C-reactive protein, microalbuminuria, nonalcoholic 
fatty liver disease and/or nonalcoholic steatohepatitis, polycystic ovary 
syndrome, and obstructive sleep apnea. 
 
 
 
METABOLIC SYNDROME AND MICROALBUMINURIA 
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NONALCOHOLIC FATTY LIVER DISEASE 
Fatty liver is a  relatively common condition, affecting 25–45% of the U.S. 
population. 
However, in the nonalcoholic steatohepatitis, the triglyceride accumulation and 
the inflammation coexist. Nonalcoholic steatohepatitis is now present in the 3–
12% of the population of the United States and other Western countries. Of 
patients with the metabolic syndrome, ~25–60% have nonalcoholic fatty liver 
disease and up to 35% have nonalcoholic steatohepatitis. As the prevalence of 
overweight/obesity and the metabolic syndrome increases, nonalcoholic 
steatohepatitis may become one of the more common causes of end-stage liver 
disease and hepatocellular  carcinoma among the study population. 
HYPERURICEMIA 
Hyperuricemia reflects defects in insulin action on the renal tubular 
reabsorption of uric acid in the renal system and may contribute to hypertension 
through its effect on the endothelium in the blood vessels . An increase in 
asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, 
also relates to endothelial dysfunction. In addition, the microalbuminuria may 
be caused by altered endothelial pathophysiology in the insulin-resistant state of 
the body. 
POLYCYSTIC OVARY SYNDROME 
Polycystic ovary syndrome is highly associated with the  insulin resistance (50–
80%) and the metabolic syndrome, with a prevalence of the syndrome between 
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40%and 50%. Women with polycystic ovary syndrome are two to four times 
more likely to have the metabolic syndrome than are women without polycystic 
ovary syndrome and its manifestation. 
 
OBSTRUCTIVE SLEEP APNOEA 
Obstructive sleep apnea is commonly associated with obesity, hypertension, 
increased circulating cytokines, impaired glucose tolerance, and insulin 
resistance. With these associations, it is not surprising that individuals with 
obstructive sleep apnea frequently have the metabolic syndrome. Moreover, 
when the biomarkers of insulin resistance are compared between the patients 
with obstructive sleep apnea and the weight-matched controls, insulin 
resistance is found to be more severe in those with apnea. Continuous positive 
airway pressure treatment improves insulin sensitivity in patients with 
obstructive sleep apnea and its symtoms . 
 
 
  
- 18 - 
 
 
AIMS AND OBJECTIVE      : 
 
1.TO STUDY THE ASSOCIATION BETWEEN METABOLIC 
SYNDROME AND ACUTE CORONARY SYNDROME 
 
2.TO STUDY THE PREVALANCE OF METABOLIC SYNDROME IN 
ACUTE              CORONARY SYNDROME 
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REVIEW OF LITERATURE 
Metabolic syndrome 
Metabolic syndrome is defined as  a clustering of cardiovascular risk 
factors in an individual which predisposes the person to a greater risk of 
developing  the type 2 diabetes mellitus and the cardiovascular disease. 
It was first coined as syndrome X in the year 1988. 
Main feature of metabolic syndrome includes the insulin resistance. 
Criteria for diagnosis 
1) International disease federation 
2) WHO criteria 
3) National cholesterol education panel ATP III guidelines. 
 
Nomenclature 
Other names for metabolic syndrome  are the following 
Syndrome X 
Metabolic syndrome X 
Pluri metabolic syndrome 
Insulin resistance syndrome 
"deadly quartet," 
Hyper triglyceridemic waist. 
Reaven's Syndrome 
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HISTORY OF METABOLIC SYNDROME 
The term "metabolic syndrome" dates back to the  late 1950s, but came into 
common usage in late 1970s to describe various associations of risk factors 
with the diabetes that had been noted as early as the 1920s 
In 1947 Marseilles physician Dr. Jean Vague, observed that the upper body 
obesity appeared to predispose to diabetes, atherosclerosis, gout and calculi. 
Avogadro, Crepaldi and his co-workers described the six moderately obese 
patients with diabetes, hypercholesterolemia, and marked hypertriglyceridemia 
all of which improved when the patients were put on a hypocaloric, low-
carbohydrate diet. 
In 1977 and 1978, Gerald B. Phillips developed the concept that the risk factors 
for myocardial infarction concur to form a "constellation of abnormalities" (i.e., 
glucose intolerance, hyperinsulinemia ,hypercholesterolemia, 
hypertriglyceridemia, and hypertension) that is associated not only with heart 
disease but also with aging, obesity and other clinical states. He suggested that  
there must be an underlying linking factor, the identification of which could 
lead to the prevention of cardiovascular disease; he hypothesized that this factor 
was the sex hormones. 
In 1988, Gerald Reaven(1) reintroduced the concept of syndrome X for the 
clustering of cardiovascular risk factors like hypertension, glucose intolerance, 
high triglycerides, and low HDL cholesterol concentrations. The syndrome is 
however, the much older, having been already observed in 1923 by the Kylin, 
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who described the clustering of hypertension, hyperglycemia, and  the gout as a 
syndrome. 
In 1998, WHO proposed a unifying definition for the syndrome and chose to 
call it the metabolic syndrome rather than the insulin resistance syndrome. This 
name was chosen primarily because it was Not considered established that 
insulin resistance was the cause of all the components of the syndrome. 
The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of 
a constellation of metabolic abnormalities that confer increased risk of 
cardiovasculardisease (CVD) and diabetes mellitus (DM). The criteria for the 
metabolic syndrome have evolved since the original definition by the World 
Health Organization in 1998, reflecting the growing clinical evidence and 
analysis by a variety of consensus conferences and  professional organizations. 
The major features of the metabolic syndrome include the central obesity, 
hypertriglyceridemia, low HDL cholesterol, hyperglycemia, and hypertension. 
 
Epidemiology 
Prevalence of the metabolic syndrome varies across the world, in part 
reflecting the age and ethnicity of the populations  in the globe studied and the 
diagnostic criteria applied. In general, the prevalence of metabolic syndrome 
increases with the  age. The highest recorded prevalence worldwide is in Native 
Americans ,with nearly around  60% of women ages 45–49 years and 45% of 
men ages 45–49years meeting National Cholesterol Education Program, Adult 
Treatment Panel III (NCEP:ATPIII) criteria. Based on data from the National 
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Health and Nutrition Examination Survey (NHANES) III(2), the age-adjusted 
prevalence of the metabolic syndrome in the  United States is around 34% for 
men and 35% for the  women. In France, a 30–64-year-old cohort shows a 
<10% prevalence for each gender, although 17.5% are affected in the 60–64  
years of  age. Greater industrialization worldwide is associated with rising rates 
of obesity, which is anticipated to dramatically increase in the prevalence of the 
metabolic syndrome, especially as the population ages. Moreover, the rising 
prevalence and the severity of obesity in children is initiating features of the 
metabolic syndrome in a younger population. 
 
Definitions of Metabolic syndrome 
There are various definitions for metabolic syndrome. The widely used 
definitions are 
I. WORLD HEALTH ORGANISATION (WHO)3 
Clinical Measure       WHO (1988) 
Insulin resistance                                                 impaired glucose tolerance,  
Impaired fasting glucose 
                                                                          , T2DM, or lowered 
Insulin sensitivity plus 
Any 2 of the following 
Body weight       Men: waist to hip ratio>0.90 
Women: waist to hip            
 ratio>0.85 
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And/ or BMI>30 kg/ sq. m 
Lipid        TG >=150 mg/dL 
HDL cholesterol <40 mg/dL  
for the men, 
<50 mg/dL for the women 
Blood pressure      >=140/90 mmHg. 
Glucose       IGT,IFG or T2DM 
 
OTHER  microalbuminuria (Urinary 
albumin to creatinine ratio: 
30 mg per gram , or albumin 
excretion rate: 20mcgper 
minute) 
II. INTERNATIONAL DIABETIC FEDERATION4 
Clinical Measure      IDF (2005) 
Insulin resistance     None 
Body weight  Increased waist   circumference 
(population specific)Plus any 2 
of the following criteria 
Lipid        TG >=150 mg/dL or on R/ 
HDL cholesterol <40 mg/dL 
for men, 
<50 mg/dL for women or on R/ 
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Blood pressure    >=130/85 mmHg or on R/ 
Glucose      >=100 mg/dL(including diabetes) 
 
III. THE ADULT TREATMENT PANEL5 III OF THE 
NATIONAL CHOLESTEROL EDUCATION PROGRAM (2001, 2005) 
It defined the diagnosis as three or more of the following five 
1. Increased waist circumference (>=102 cm in men and >=88 cm inwomen) 
2. Elevated triglycerides (>=150 mg/dL or 1.7 mmol/l) 
3. Decreased HDL cholesterol (<40 mg/dL for men, <50 mg/dL for women) 
4. Blood pressure above 130/85 or active treatment for hypertension 
5. Glucose levels above 100 mg/dL or active treatment for hyperglycemia 
 
IV. AMERICAN HEART ASSOCIATION , 
NATIONAL HEART , LUNG AND BLOOD INSTITUTE6, JULY 2005 
SCIENTIFIC STATEMENT 
Metabolic syndrome was defined according to the AHA/NHLBI statement and  
maintaining NCEP ATP III1 criteria with minor modifications. Patients 
received a diagnosis of metabolic syndrome if they had any 3 of the following 
5 criteria: 
1. Abdominal obesity (waist circumference in men >102 cm and in women 
>88cm for western population and > 90 cm in men and > 80 cm in women of 
Asian origin) 
- 25 - 
 
2. High triglyceride levels >=150mg/dL 
3. Low HDL Cholesterol level <40 mg/dL in men and <50 mg/dL in women 
4. High blood pressure (treated hypertension, and systolic blood pressure 
>=130mm Hg, or diastolic blood pressure >= 85 mm Hg) 
5. Fasting glucose >= 100 mg/dL or on treatment for diabetes mellitus. In 
accordance with the 2003 recommendation from the American Diabetes 
Association7, in the last three definitions of IDF, Adult Treatment Panel III 
of the National Cholesterol Education Program (2001, 2005) and 
AHA/NHLBI statement the value of impaired fasting glucose was reduced 
from 110 mg/Dlto 100 mg/dL.When the waist circumference is 90 cm or 
more in men or 80 cm or more in women, the term abdominal obesity can be 
applied. The advantage of measuring waist circumference is that an excess 
abdominal fat is correlated more closely with the presence of metabolic risk 
factors than total body fat. 
 
GENETICS 
A "thrifty genotype hypothesis" implicates the evolutionary selection of 
metabolic genes in the development of the metabolic syndrome in the setting of 
the modern environment of physical inactivity and dietary excess. Family 
studies suggest a complex but significant genetic basis to the  individual 
components of the metabolic syndrome. However, identifying a genetic profile 
that defines an increased risk of developing a complex disease trait, such as the 
metabolic syndrome or  the atherosclerosis, remains difficult to elucidate. 
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Concept of genes predisposing to metabolic syndrome 
Mutations in the PPAR  gene that disrupt the function of the protein 
causes severe IR,(savage et al 2003)8 ,Dyslipidemia and  the Hypertension 
Calpain 10 gene is the important in modification and processing of 
proteins in the cell.(sang et al)9. 
Variants in calpain gene alter the risk to Type 2 DM. Variants in SUR & 
kir 6.2 cause rare a diabetes related disorders & predispose to the  Type 2 
DM10. 
Mutations in HNF1 . HNF-4  and rarely in GCK gene cause MODY. 
 
Biomarkers of metabolic syndrome11 
 
Lipid and 
Lipoproteins 
Low density 
lipoprotein Vascular injury 
Adipokines 
Leptin 
Adiponectin 
Resistin 
Modulation of insulin 
sensitivity . 
Anti-inflammatory 
action. 
Impairment of the  
glucose 
tolerance. 
Inflammatory 
Markers 
C-reactive protein 
TNF alpha receptor 2 
Interleukin -6 
Interleukin-8 
Endothelial dysfunction 
Insulin resistance 
Athero thrombosis. 
Chemokines Monocyte 
chemotactic protein 
Neutrophils attraction to 
The endothelium. 
Haemostatic markers Plasminogen 
activator inhibitor 1 
Induction of cell the  
adhesion molecule 
expression. 
Insulin resistance. 
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Risk Factors 
Overweight / Obesity 
Central adiposity is a key feature of the syndrome, reflecting the fact that 
the syndrome's prevalence is the driven by the strong relationship between 
waist circumference and the increasing adiposity. However, despite the 
importance of obesity, patients who are normal weight may also be insulin-
resistant and have the metabolic syndrome. 
Sedentary Lifestyle 
Physical inactivity is the most important predictor of cardiovascular 
events and related mortality. Many components of the metabolic syndrome are 
associated with a sedentary lifestyle ,including increased subcutaneous adipose 
tissue  in (predominantly central); reduced HDL cholesterol; and a trend toward 
the increased triglycerides, high blood pressure, and high blood glucose levels 
in the genetically susceptible. Compared with individuals who watched 
television or the videos or used their computer <1 hour daily, those who carried 
out these behaviors for >4hours daily have a twofold increased risk of the 
metabolic  syndrome. 
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PATHOPHYSIOLOGY -MECHANISTIC LINKS BETWEEN  
COMPONENTS 
INSULIN RESISTANCE 
Insulin resistance per se is independently an atherogenic phenomena. Insulin 
resistance is the pathophysiological process underlying the clustering of 
cardiovascular risk factors in the metabolic syndrome12,13. In prospective 
studies, the presence of insulin resistance is associated with increased ASCVD 
risk14. Some of the risk factors that are hallmark of insulin resistance—for 
example, abnormal lipid levels, the glucose intolerance, and the  high blood 
insulin levels—appear to provide a fertile ground for the development of 
serious chronic diseases such as diabetes, heart disease, and fatty liver. For the  
instance, high blood insulin levels have been linked to the hypertension, while 
insulin resistance appears to  be to promote atherosclerosis. 
 
Multiple metabolic pathways have been proposed to link insulin 
resistance and the compensatory hyperinsulinemia to the other metabolic risk 
factors13,15. 
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PATHOPHYSIOLOGY  OF METABOLIC SYNDROME 
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This is true for many individuals of the South Asian ethnicity16,17. Although 
insulin resistant individuals need not be clinically obese, they have an abnormal 
fat distribution that is characterized by predominant upper body fat. 
Asymmetric dimethylarginine (ADMA), a naturally occurring molecule , is 
increased in  the metabolic syndrome . It inhibits the synthesis of nitric oxide, 
which is a potent dilator of blood vessels. ADMA also increases the binding of 
the  white blood cells to the endothelial lining of arteries, which may contribute 
to the atherosclerosis. 
Indices of insulin resistance predict atherosclerosis and cardiovascular events 
independent of other risk factors including fasting glucose and lipid levels18. 
Many subjects with the normal fasting glucose levels have insulin 
resistance12.The hyperinsulinemic clamp is considered to be the gold standard 
to define insulin sensitivity but requires prolonged insulin infusion and repeated 
blood sampling. Surrogate measures of insulin sensitivity, including the 
Homeostasis Model Assessment (HOMA) and Quantitative Insulin Sensitivity 
Check Index(QUICKI), have been developed that can be applied to single 
measurements of fasting insulin and glucose. These surrogates are useful in 
defining the MetSyn and in predicting the development of  the cardiovascular 
disease and type 2 diabetes mellitus18,19. 
Insulin resistance is thought to  be the contributor  to the accumulation of fatty 
deposits in the liver. Insulin resistance also has been implicated in polycystic 
ovary syndrome20and nonalcoholic steatohepatitis (NASH). 
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Innate immunity and inflammation play a role in the development of insulin 
resistance and predict the development of type 2diabetes mellitus21,22. Thus, the 
pathophysiology of insulin resistance and atherosclerotic cardiovascular events 
may have a common proximal inflammatory basis. 
 
DYSGLYCEMIA 
In cross-sectional and prospective studies, fasting and postprandial glucose an 
insulin concentrations are positively correlated to the metabolic syndrome. The 
increase in insulin concentrations is paralleled by a decrease in insulin 
sensitivity. Decreased insulin sensitivity leads to defects in the ability of the 
insulin to inhibit hepatic glucose production and to stimulate glucose uptake in 
peripheral tissues and thereby leading to the  hyperglycemia. 
Increased FFA concentrations and resistance to the antilipolytic effect of insulin 
may contribute to the worsening of hyperglycemia23 because of the  multiple 
interactions between the  FFA and glucose metabolism both in the liver and 
also in skeletal muscle. A variety of mechanisms to explain how elevated 
plasma glucose may promote the atherosclerosis are postulated24. 
A variety of mechanisms have been proposed whereby hyperglycemia might 
promote the  atherosclerosis 24. Examples include nonenzymatic glycosylation 
of lipids and the  proteins, pathogenic effects of advanced glycation 
products,increased oxidative stress free radicals , activation of protein kinase C, 
and microvascular disease of the vasa vasorum of the coronary arteries in the 
heart. 
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OBESITY AND ABDOMINAL OBESITY 
Obesity is related to insulin resistance25,26 Obesity is associated with impaired 
insulin stimulation of glucose uptake and defect in the ability of insulin to 
inhibit endogenous glucose production and lipolysis in the adipose tissue of the 
body. These defects will appear more severe in individuals with android 
(abdominal fat distribution) than the gynoid obesity. 
Upper-body obesity correlates strongly with the insulin resistance. Excess 
visceral fat deposition than the subcutaneous fat deposition is strongly 
associated with the insulin resistance. Excess subcutaneous abdominal (or 
truncal) fat also carries a significant association with the insulin resistance27-
32
.An interesting feature of upper-body obesity is a high release of nonesterified 
fatty acids from adipose tissue in to the blood stream33,34; this contributes to 
accumulation of lipid in sites other than adipose tissue. Ectopic lipid 
accumulation in muscle and liver seemingly predisposes to insulin 
resistance35and dyslipidemia36. 
The foremost physical consequence of obesity is atherosclerotic cardiovascular 
disease (ASCVD)37,38. The majority of obese persons who develop ASCVD 
typically have metabolic syndrome. 
Body mass index is  relatively insensitive indicator for the metabolic and 
cardiovascular complications of obesity, as compared with measures of central 
or abdominal adiposity39. Waist circumference reflects both abdominal 
subcutaneous adipose tissue(SAT) and abdominal visceral adipose tissue 
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(VAT) and is the general index of central(trunk) fat mass. So, waist 
circumference is preferred more for measuring the  abdominal obesity. VAT 
has been proposed as the major determinant of metabolic and cardiovascular 
complications of obesity40. 
Our understanding of the relation between obesity and metabolic risk factors is 
growing rapidly. This understanding is based on the discovery of multiple 
products released from adipocytes like 41. 
Nonesterified fatty acids (NEFAs) 
Inflammatory cytokines 
PAI-1 
Adiponectins 
Leptins 
Resistins 
Circulating cytokines have systemic effects, i.e. promoting insulin resistance in 
the  muscle42, increased synthesis of the acute-phase reactants in the liver (CRP 
and fibrinogen), or activation of macrophages in atheromatous plaques43. 
Excessive influx of NEFAs into the muscle leads to insulin resistance. Randle 
et al44 postulated that the excess fatty acids in muscle inhibit the glucose 
oxidation (glucose-fatty acid cycle). Recent research suggests that the muscle 
levels of diacylglycerol are raised, which stimulates the serine phosphorylation 
of the  insulin receptors and thereby inhibits normal insulin signaling. Other 
mechanisms also may play a role in insulin resistance in the muscle45. 
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Fat accumulation in the liver seemingly to  produces insulin resistance as it 
does in muscle also. Reduction in insulin action in liver allows for enhanced 
gluconeogenesis and increased hepatic glucose output. 
Hypotheses have been developed to link higher NEFA levels to higher blood 
pressures46. Accumulation of fat in the liver has been reported to be associated 
with the  increased hepatic synthesis of PAI-1, fibrinogen, and inflammatory 
cytokines, the key mediators of the prothrombotic and proinflammatory 
states47. 
Adipose tissue synthesizes PAI-1. A fatty liver may be the  another source of 
PAI-1 production.The resulting high PAI-1 levels in the obese persons together 
with the high plasma fibrinogen observed in such persons contributes to a 
prothrombotic state. 
Adiponectin48 is reported to have an antiinflammatory and antiatherogenic 
properties. Obese persons generally have low levels of adiponectin and hence 
may be deprived of its protective effects against the metabolic syndrome. 
Leptin also may play a systemic role beyond being an adipose tissue-derived 
appetite suppressant substance. This hormone has been reported to have a 
beneficial effect on the liver to protect against the fatty liver49,50. Its mechanism 
may be to enhance fatty acid oxidation in the liver. Finally, resistin is an 
adipose tissue-derived hormone that seemingly opposes the action of insulin in 
the body51. 
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DYSLIPIDEMIA 
Dyslipidemia is a hallmark of the metabolic syndrome and is characterized by 
the elevated triglycerides (TG) and low levels of HDL-C. Increased fat in the 
liver provides a stimulus for the increased formation and the secretion of very 
LDL (VLDL) particles. The result is higher serum levels of triglyceride, apo B, 
and small LDL particles. High serum triglycerides reduce HDL-cholesterol 
concentrations through exchange of VLDL triglycerides with HDL 
cholesterolesters lipoproteins. 
HYPERTRIGLYCERIDEMIA 
Influx of excess NEFAs into the liver increases the triglyceride content of the 
liver (fatty liver)52. Increased flux of free fatty acids from the periphery to the 
liver in the insulin-resistant state drives hepatic TG synthesis, which in turn 
promotes the assembly and secretion of TG-containing VLDL. 
Insulin normally suppresses the production of VLDL particles from the liver by 
directly inhibiting the assembly and production of VLDL particles53. In insulin 
resistance this action of Insulin is lost leading to the increase in serum 
triglycerides54.Under hypertriglyceridemic conditions, there is an excessive 
exchange of cholesterol esters and triglyceride-rich lipoproteins, mediated by 
the  cholesterol ester transfer protein. 
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LOW HDL CHOLESTEROL 
Metabolic syndrome is associated with the  low HDL cholesterol. HDL 
particles become enriched with the triglycerides55 and act as good substrate for 
hepatic lipase which now removes HDL particles at an accelerated rate than 
thought before. This is mediated by mediated by the cholesteryl ester transfer 
protein. Subnormal activity of lipoprotein lipase may further decrease level of 
HDL cholesterol in the blood. Activation of innate immunity offers a potential 
unifying pathophysiology for insulin resistance and dyslipidemia in the 
metabolic syndrome than thought before. In animal models, activation of innate 
immunity leads to changes in lipoproteins ,enzymes, transfer proteins, and 
receptors with an increase in atherogenic lipoprotein particle molecule. One 
possible contributor to the changes in HDL during inflammation is the 
increased production of lipases that act on HDL phospholipids, thus reducing 
the lipid content of HDL and promoting its catabolism in the body. 
A low HDL level is another characteristic of atherogenic dyslipidemia. As an 
risk predictor, a low HDL rivals an elevated total apo B lipoprotein (or 
VLDL+LDL cholesterol). This fact has led to the concept that HDL is 
intimately involved in the atherogenic  process in the body. The theories 
abound as to the mechanisms whereby HDL is antiatherogenic are enhanced 
reverse cholesterol transport, antiinflammatory properties, ability to protect 
against the  LDL modification. Although HDL in fact may be directly 
antiatherogenic and  it also is a marker for the presence of other lipid and 
nonlipid  risk factors. 
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SMALL DENSE LDL PARTICLES 
In metabolic syndrome LDL particles are smaller and denser than normal. 
Small dense LDL particles are known to be highly atherogenic 56 than others 
and provide aplausible link between the  insulin resistance and the 
cardiovascular disease. 
The increase in the triglyceride content of LDL particles57 makes them a better 
substrate for the  hepatic lipase which hydrolyzes triglycerides in the LDL 
particles and so decrease their size. 
High levels of the circulating oxidised LDL, which is increased in metabolic 
syndrome are associated with a greater disposition to atherothrombotic 
coronary disease58. A theory widely held is that smaller LDL particles are more 
atherogenic than larger LDLs59. Small LDL particles are a surrogate for an 
increased LDL particle number60 . 
A simple strategy for assessing the sum of the atherogenic particles is 
measurement of either LDL+VLDL cholesterol (non-HDL cholesterol) or total 
apoB . In persons with metabolic syndrome, both LDL+VLDL cholesterol and 
total apoB typically are elevated. These measurements should be used 
increasingly both in the  risk assessment and as targets of therapy in persons 
with the metabolic syndrome61. 
HYPERTENSION 
The association between the insulin resistance and hypertension is perhaps the 
most controversial. In insulin resistant patients with essential hypertension , the 
basal intracellular calcium levels have been shown to be elevated and the 
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normal ability of insulin to attenuate angiotensin II induced increases in 
intracellular calcium is blunted in skin fibroblasts in the body62. 
The renal action of insulin is  to reabsorb sodium is similar in normo- and also 
in  hypertensive insulin-resistant subjects. Such a preserved action of insulin 
may contribute to an increase in the blood pressure in hyperinsulinemic 
individuals63. 
Insulin resistance has  been consistently found to correlate with high sodium-
lithium counter-transport in the  erythrocyte membranes: this is thought to be 
parallelly increased activity of the sodium hydrogen ion pump in the cell 
membrane of other tissues ,which could raise the intracellular sodium and 
calcium concentrations and enhance vascular muscle contractility. Such action 
could also contribute to the development of hypertension in non-diabetic, 
insulin resistant subjects. 
A higher blood pressure is a strong risk factor for cardiovascular disease 
(CVD)64. Well-known complication of hypertension are CHD, stroke, left 
ventricular hypertrophy, heart failure, and chronic renal failure. Hypertension is 
particularly dangerous to the cardiovascular system. This concept supported by 
the well known Framingham Heart Study65. 
 
Hyperuricemia 
Within the non-diabetic range of glucose tolerance, serum uric acid 
concentrations are positively correlated with the  glucose and insulin 
concentrations and inversely with the  insulin resistance66. 
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In normal subjects, insulin acutely reduces the renal clearance of both sodium 
and uric acid levels67. These actions are preserved in insulin resistant states 
such as obesity, diabetes and essential hypertension and so provide a potential 
mechanistic link for the clustering of the insulin resistance with 
hyperuricemia68. 
 
ALTERATIONS IN COAGULATION, FIBRINOLYSIS AND 
PLATELET FUNCTION 
Metabolic syndrome is also associated with a proinflammatory/prothrombotic 
state that includes the elevated levels of the C-reactive protein, endothelial 
dysfunction ,hyperfibrinogenemia, increased platelet aggregation, increased the 
levels of plasminogenactivator inhibitor 1, elevated uric acid levels and  
microalbuminuria Pro-coagulant changes such as impaired fibrinolysis and 
increased levels of the  PAI-I and defects in platelets function are frequently 
associated with insulin resistance. PAI-I, an inhibitor of fibrinolysis, is elevated 
in obesity associated insulin resistance69. 
Coagulation and  the fibrinolytic abnormalities cause endothelial dysfunction, 
which in turn is involved in the atherogenic process70. 
 
CHANGES IN INFLAMMATORY MARKERS 
IL-6 , the main regulator of the synthesis of C-reactive protein in the liver71 is 
increased in metabolic syndrome.  Upto one third of the circulating IL-6 
originate from the subcutaneous and visceral adipose tissue depots and 
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circulating levels are increased in obese subjects72.Recently, this syndrome has 
been noted to be associated with the  state of chronic, low-grade 
inflammation73,74. It is of  the interest that obese persons75 and particularly those 
with the metabolic syndrome76 also have  the elevated levels of CRP 
 
MICROALBUMINURIA 
The mechanisms underlying the clustering of insulin resistance and 
microalbuminuria are poorly understood even with large studies. Insulin has 
been shown to increase urinary excretion of albumin and protein markers of 
proximal tubular function in diabetic patients but not in nondiabetic 
individuals77. Microalbuminuria may also be a sign of preclinical endothelial or 
vascular damage78. 
 
ABNORMALITIES IN THE AUTONOMIC NERVOUS SYSTEM 
In insulin resistant subjects, insulin can enter the hypothalamus and other parts 
of the brain, where insulin receptors are expressed at high levels, and it acts 
centrally to stimulate the sympathetic nervous system79. Insulin also regulates 
the autonomic control of heart rate by the decreasing vagal tone, and increasing 
sympathetic drive80. 
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ACUTE MYOCARDIAL INFARCTION AND METABOLIC 
SYNDROME 
In prospective epidemiologic studies, hyperinsulinemia is an independent risk 
factor for  the devolepment ofCHD in the non-diabetic men after adjusting for 
body weight, blood pressure and dyslipidemia81.This study also reveals that  the 
patients with an AMI and no previous diagnosis of diabetes mellitus have a 
high prevalence of insulin resistance82 . There has been consistent relationship 
of metabolic syndrome with prevalent of  MI and stroke83. 
In men participating in the West of Scotland Coronary prevention Study, the 
insulin resistance syndrome  is defined as  according to NCEP criteria increased 
the risk for the CHD event by 1.76 fold. Men with  the four to five features of 
the syndrome had a 3.7 fold increase in risk for  the CHD. 
 
OTHER MARKERS OF METABOLIC SYNDROME AS PREDICTORS 
OF CARDIOVASCULAR DISEASE 
C-reactive protein has predicted  the cardiovascular disease independent of 
other risk Factors .Hyperuricemia is associated with increased mortality from 
all causes of the cardiovascular disease in the NHANES I2 epidemiologic 
survey in women but not in men. The PAI-I has been found predictive for 
cardiovascular disease in several studies84. Microalbuminuria increased the 
relative risk of CHD death eightfold and of all CHD events threefold even after 
adjusting for gender, smoking, blood pressure and HDL cholesterol85. 
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All these predictors of  the cardiovascular disease namely CRP, hyperuricemia, 
PAI-I and microalbuminuria are strongly associated with metabolic syndrome. 
 
MANAGEMENT OF METABOLIC SYNDROME  
Metabolic syndrome is the secondary target for reducing cardiovascular events. 
Smoking cessation, lowering the levels of LDL-C, and blood pressure 
management are primary target for risk reduction. Lifestyle modifications are 
the initial therapies recommended for treatment of metabolic syndrome. If 
lifestyle change is not a sufficient, then drug therapies may be indicated for the 
management. To date, there is insufficient evidence for primary use of  the 
drugs that target the underlying causes of metabolic syndrome. 
 
LIPOPROTEINS: 
Lipoproteins are the complexes of lipids and proteins that are essential for 
the transport of cholesterol, triglyceride and fat soluble vitamins. It contains a 
core of hydrophobic lipids triglycerides and cholestryl esters surrounded by 
hydrophilic lipids phospholipids and unesterified cholesterol and proteins that 
interact with the body fluids86. 
Plasma lipoproteins are divided into five major classes based on 
their relative density. 
Chylomicrons 
 Very low density lipoproteins 
 Intermediate density lipoproteins 
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 Low density lipoproteins 
 High density lipoproteins. 
HDL is the smallest and most dense lipoprotein, chylomicron and VLDL 
are the largest and least dense lipoprotein. 
The proteins associated with lipoproteins are called apolipoproteins they 
are required for the assembly structure and function of lipoproteins. 
APO A1 synthesized in the liver and intestine is found in all HDL 
particles. 
APO B 48 –contains chylomicrons 
APO B 100-VLDL, IDL or LDL. 
 
 
 
METABOLISM OF LIPO PROTEINS 
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Transport of dietary lipids 
Exogenous pathway87 
Dietary triglycerides are hydrolyzed by lipoprotein lipases within the 
intestinal lumen and emulsified with bile acids. 
Cholesterol and retinol are esterified to form the cholestryl esters and 
retinyl esters. 
Longer chain fatty acids are incorporated into triglycerides and packaged 
with APO B 48 cholestryl esters, phospholipids and cholesterol to form the 
chylomicrons. 
Nascent chylomicrons are secreted into intestinal lymph and delivered 
via thoracic duct to systemic circulation. 
They become chylomicrons when  the nascent particles combine with 
apo CII and apo E derived from HDL. 
The enzyme lipoprotein lipase present in capillary walls of adipose 
tissue cardiac and skeletal muscle hydrolyses the triacylglycerol present in the 
chylomicrons and releases  the free fatty acids and the  glycerol. 
Lipoprotein lipase is activated by the apo CII. 
The chylomicron remnants are taken up by the receptors present on the 
hepatocytes of the liver. 
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TRANSPORT OF LIPO PROTEINS 
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Endogenous pathway88 
 VLDL particles resemble  the chylomicrons in protein composition 
but contain the APO B 100. 
 Packaging of the hepatic triglycerides with other components of the  
nascent      VLDL   particle require the action of MTP. 
 Triglycerides are formed due to the esterification of  the long chain 
fattyacids in the liver. 
 After  the secretion into the plasma VLDL acquires APO CII and 
APO from  the HDL. 
 VLDL are also hydrolyzed by lipoprotein lipase especially in the  
muscle and  adipose tissue. 
 They lose the  APO CII after which IDL is formed. 
 It loses  the APO E and gets converted to LDL. 
 LDL contains high cholesterol and less triacylglycerol. 
 the cholestrol in LDL accounts for over half of the plasma  cholesterol 
in most          individuals. 
 Approximately 70% of the  LDL cholesterol is cleared by LDL 
receptor mediated endocytosis in the liver. 
Investigations to be done in case of metabolic syndrome 
 Fasting lipid level 
 Fasting glucose 
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 Liver function test. 
 APO B 
 High sensitivity –CRPs 
 Fibrinogens 
 Uric acids 
 Sleep study if the  obstructive sleep apnea is  present 
 Testosterone, luteinizing hormone, follicle stimulating hormone in 
case of polycystic ovary disease. 
 Urinary microalbumin. 
Treatment of metabolic syndrome 
Life style 
Weight reduction is the first and foremost approach to this disorder. 
Recommendations for weight loss is calorie restriction with increased physical 
activity and behavioural modification89. 
Diet- 
500 kcal restriction is adviced daily . carbohydrate restricted diet provide 
a rapid initial weight loss. 
Physical activity 
Increase in the  physical activity leads to weight reduction. 60-90 min of 
daily walking activity is required to achieve this goal90. 
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Obesity 
Weight loss drugs can also be used. Drugs like phentermine and 
sibutramine, orlistat inhibits fat absorption. bariatric surgery are other and final 
options91. 
LDL cholesterol 
 Diet restricted in the saturated fats. 
 HMG COA reductase inhibitors are the first choice of drugs. 
 Ezetimibe is  second choice. 
 Bile acid sequestrants are more effective. 
 cholestyramine and cholestipol. 
 Nicotinic acid 
 Fenofibrates are the other drugs which can also be used. 
Triglycerides 
Weight reduction 
Gemfibrozil or fenofibrate is the drug of choice to lower fasting 
triglycerides92. 
Other drugs are statins nicotinic acid and omega 3 fatty acid 
preparations. 
HDL cholesterol 
Nicotinic acid is the only available drug to raise the  HDL cholesterol. 
Blood pressure 
In patients with metabolic syndrome with diabetes ACE inhibitors or 
ARB are used93. 
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Impaired fasting glucose 
Metformin has been showed to reduce the incidence of diabetes. Insulin 
resistance Both metformin and thiazolidinediones increase insulin sensitivity. 
 
Blood supply of heart 
Heart is supplied by two coronary arteries arising from the sinus of 
ascending aorta.both of which run in the coronary sulcus. 
 
Right coronary artery94 
Is smaller than the left coronary artery .It arises from the anterior  aortic  
sinus. 
Branches 
Large branches 
Marginal 
Posterior inter ventricular 
Small branches 
Nodal 
Right atrial 
Infundibular and terminal. 
Area of distribution 
Right atrium 
Ventricles 
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Greater part of the right ventricle except the area adjoining the anterior 
interventricular groove. 
A small part of the left ventricle adjoining the posterior interventricular 
groove.Posterior part of interventricular septum. 
Whole of the conducting system of the heart except the part of the left 
branch of AV bundle. 
Left coronary artery95 
Larger than the right coronary artery.arises from the left posterior aortic 
sinus. 
 
Branches 
Large branches 
Anterior interventricular 
         Branches to the diaphragmatic surface of left ventricle. 
         Diagonal branch. 
Area of distribution 
Left atrium 
Ventricles 
Greater part of the left ventricle except the area adjoining the posterior     
interventricular groove. 
A small part of the right ventricle adjoining the anterior  interventricular 
groove.Anterior part of the interventricular septum. 
A part of left branch of AV bundle. 
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Acute coronary syndrome96 
They are patients whose clinical presentation cover the following range 
of diagnosis. 
ST segment elevation myocardial infarction 
Non ST segment elevation MI 
Unstable angina. 
The first step is to a detailed description of the symptom complex in 
order to characterize the chest pain or discomfort. Five descriptors typically are 
considered in the following. 
1. Location, 
2. Quality, 
3. Duration of the discomfort, 
4. Inciting factors, and 
5. Factors relieving pain 
Clinical classification of angina 
Typical angina (definite) 
1. Substernal chest discomfort with a characteristic quality and duration 
that is 
2. Provoked by exertion or emotional stress and 
3. Relieved by rest or nitroglycerin. 
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ACUTE CORONARY SYNDROME 
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Atypical angina (probable) 
Meets two of the above characteristics symptoms. 
Noncardiac chest pain 
Meets one or none of the typical anginal characteristics. 
Stable Angina: 
Stable angina is characterized by a deep, poorly localized chest or arm 
discomfort (rarely described as pain) that is aggravated with physical exertion 
or emotional stress and relieved within 5 – 15 minutes by rest or sublingual 
nitroglycerine, or both. The characteristics of the stable angina usually 
Unchanged for 60 days. 
Unstable angina is diagnosed mainly based on clinical presentation97.  
Unstable angina is defined as angina pectoris or equivalent. ischaemic 
discomfort with atleast one of the three features. 
It occurs at rest usually lasting for more than 10 minutes. 
Severe and of new onset within the prior 4-6 weeks 
Occurs with a crescendo pattern. 
Diagnosis of NSTEMI is established if a patient with the clinical features of 
unstable angina also has have elevated cardiac biomarkers due to myocardial 
necrosis. 
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Patho physiology 
Plaque rupture or erosion. 
Coronary spasm 
Progressive mechanical obstruction. 
Secondary unstable angina. 
Clinical features 
Chest pain typically located in the substernal region or sometimes in the 
epigastrium that radiates to the neck, left shoulder and chin. Anginal 
equivalents such as dyspnea, fatigue, epigastric discomfort, faintness and 
eructations.. 
Crescendo Angina: worsening of angina can be defined as symptoms 
that result in at least 1 Canadian Cardiovascular Society(CCS) class increase or 
to at least CCS Class 3 severity. 
Secondary Unstable Angina: 
This form of unstable angina is precipitated by the imbalance in 
myocardial oxygen supply and demand caused by condition extrinsic to the 
coronary arteries in patients with  the prior coronary stenosis and chronic stable 
angina. 
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         CANADIAN CARDIOVASCULAR SOCIETY(CCS) GRADING: 
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PATHOBIOLOGY OF ACUTE CORONARY SYNDROME 
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PRECIPITATING FACTORS 
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 The classic World Health Organization criteria for an acute MI98 require 
that  the two of the following three elements be present: 
1. A history suggestive of coronary ischemia for prolonged period     
(>30 min), 
2. Evolutionary changes in the serial ECGs suggestive of MI, ST 
segment elevation greater than 1mm in two contiguous limb leads and greater 
than the  2mm in two contiguous chest leads. 
3. A rise and fall in serum cardiac markers consistent with  the 
myonecrosis 
The pain of myocardial infarction is typically  the substernal, diffuse, 
with a squeezing or pressure quality. It may radiate to the neck or to the  jaw, 
shoulders, or arms. Most often, the pain is accompanied by additional 
symptoms, such as lightheadedness, nausea or vomiting, diaphoresis, or 
shortness of breath. The symptoms of  the myocardial infarction last longer 
than 30 minutes, and do not respond completely to the nitroglycerin. Elderly or 
diabetic patients are prone to atypical symptoms, such as nausea or dyspnea as 
the sole symptoms of infarction. As many as one fourth of myocardial 
infarctions are “silent” — that is, whatever the symptoms were present did not 
impress the patient enough to seek medical care, or even to the  remember the 
incident. 
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MYOCARDIAL INFARCTION 
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METHODOLOGY 
STUDY DESIGN    :       PROSPECTIVE STUDY 
STUDY PERIOD    :        MARCH 2017  TO  AUGUST 2017 
STUDY POPULATION   : About 50 Patients admitted in ICCU  
INCLUSION CRITERIA 1.Patients with Acute STEMI, NON 
STEMI, UNSTABLE ANGINA   
      2. Both males and female 
EXCLUSION CRITERIA :  
1. Age less than 18 years  
2. Known coronary artery disease patient 
3. Patients refusal to participate 
4. Patients with hypothyroidism                                            
5. Patients with familial 
hypercholesterolemia 
 
STUDY PLACE         :Thanjavur Medical College & Hospital, 
            Thanjavur. 
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INVESTIGATIONS : 
• WAIST CIRCUMFERENCE 
• BLOOD PRESSURE 
• FASTING BLOOD SUGAR 
• SERUM TRIGLYCERIDES 
• SERUM HDL 
• A 12 LEAD ELECTROCARDIOGRAM 
• ECHOCARDIOGRAM 
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STATISTICAL ANALYSIS AND RESULTS 
Table 1: Distribution of age in the study groups based on the metabolic 
syndrome 
 
S. 
No 
Age (in years) 
NMS group 
(n=38) 
MS group 
(n=12) 
N % n % 
1 <40 1 2.6 2 16.7 
2 40-49 7 18.4 0 0 
3 50-59 15 39.5 5 41.7 
4 60-69 12 31.6 4 33.3 
5 ≥70 3 7.9 1 8.3 
 
Data are expressed as absolute numbers with percentage. NMS = Patients with 
Acute coronary syndrome only. MS = Patients with Acute coronary syndrome 
and Metabolic syndrome. 
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Table2: Comparison of age in years between the groups in the study 
population 
 
S. 
No 
Age in 
years 
NMS group MS group P 
value 
Statistical 
test N Mean SD n Mean SD 
1 Overall 38 56.34 9.09 12 55.5 11.8 
0.796 
(NS) 
Unpaired 
‘t’ test 
2 
Male 
gender 
29 54.9 9.55 9 52.7 11.65 
0.584 
(NS) 
Unpaired 
‘t’ test 
3 
Female 
gender 
9 61 5.59 3 63.6 10.02 
0.56 
(NS) 
Unpaired 
‘t’ test 
 
Data are expressed as mean with standard deviation. Unpaired ‘t’ test was used 
to test the level of significance. 
Both the group are comparable in respect to age i.e when age factor is 
considered both the groups are of same age because P value is not significant. 
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Table 3: Prevalence of metabolic syndrome according to the gender 
 
S. 
No 
Group name 
Male 
(n=38) 
Female 
(n=12) 
Overall 
(n=50) 
n % n % n % 
1 
NMS Group 
(Only ACS) 
29 76.3 9 75 38 76 
2 
MS Group 
(ACS with 
Metabolic 
syndrome) 
9 23.7 3 25 12 24 
P value 0.99 (NS) – Fisher’s exact test -- --- 
 
Data are expressed as absolute numbers and percentage.  
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Fig.1Prevalence of metabolic syndrome according to the gender 
Data are expressed as absolute percentage 
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Table 4: Distribution of type of MI of study population between the 
groups. 
 
S. 
No 
Type of MI 
NMS Group 
(Only ACS)  
(n=38) 
MS Group 
(ACS with 
Metabolic 
syndrome) 
(n=12) 
Overall 
(n=50) 
N % n % n % 
1 ASMI 4 10.5 1 8.3 5 10 
2 AWMI 21 55.3 5 41.7 26 52 
3 IWMI 10 26.3 4 33.3 14 28 
4 NSTEMI 2 5.3 1 8.3 3 6 
5 
Unstable 
Angina 
1 2.6 1 8.3 2 4 
 
Data are expressed as absolute numbers and percentage. 
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Table 5: Comparison of the risk factors for the Acute coronary syndrome 
between the groups. 
 
S. 
N
o 
Risk factor 
NMS Group 
(Only ACS)  
(n=38) 
MS Group 
(ACS with 
Metabolic 
syndrome) (n=12) 
P  
value 
n % n % 
1 Diabetes 
Yes 4 10.5 4 33.3 0.081  
(NS) No 34 89.5 8 66.7 
2 Hypertension 
Yes 6 15.8 8 66.7 
0.0016* 
No 32 84.2 4 33.3 
3 Smoking 
Yes 7 18.4 1 8.3 0.66 
(NS) No 31 81.6 11 91.7 
4 Alcohol 
Yes 14 36.8 3 25 0.51 
(NS) No 24 63.2 9 75 
5 
Family 
history of MI 
Yes 8 21.1 4 33.3 0.44 
(NS) No 30 78.9 8 66.7 
 
Data are expressed as absolute numbers with percentages. Fisher’s exact test 
was used to test the level of significance. Odd’s ratio for hypertension is 5.14 
(95% CI= 1.8 to 14.4) 
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Figure 2: Comparison of occurrence of hypertension between the groups in 
the study population 
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Table 6: Distribution of hypertension grading in two groups of the study 
population 
 
S. 
No 
Type of MI 
NMS Group 
(Only ACS) 
(n=38) 
MS Group 
(ACS with 
Metabolic 
syndrome) 
(n=12) 
Overall 
(n=50) 
n % n % n % 
1 Normal BP 24 63.2 5 41.7 29 58 
2 
Stage 1 
Hypertension 
11 28.9 6 50 17 34 
3 
Stage 2 
Hypertension 
2 5.3 1 8.3 3 6 
4 
Stage 3 
Hypertension 
1 2.6 0 0 2 4 
 
Data are expressed as absolute numbers and percentage. 
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Table 7: Comparison of biochemical parameters between the groups in the 
study population 
 
S. 
N
o 
Type of MI 
NMS Group 
(Only ACS)  
(n=38) 
MS Group 
(ACS with 
Metabolic 
syndrome) (n=12) 
P  
value 
Statistica
l test 
Mean SD Mean SD 
1 
Fasting blood 
sugar (mg/dl) 
91 38.4 143.3 84.2 0.004* 
Unpaired 
‘t’ test 
2 
Fasting 
triglycerides 
(mg/dl) 
88.2 21.5 144 61.7 
<0.0001*
* 
Unpaired 
‘t’ test 
3 HDL (mg/dl) 41 5.73 39.5 6.25 
0.44 
(NS) 
Unpaired 
‘t’ test 
4 
Total 
Cholesterol 
(mg/dl) 
144.3 29.3 166.2 37.2 0.039* 
Unpaired 
‘t’ test 
Data are expressed as mean with standard deviation. * indicates p value <0.05 
which is considered highly significant. ** indicates p<0.0001 which is 
considered extremely significant. 
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Table 8: Comparison of waist circumference between the groups in the 
study population 
 
S. 
N
o 
Waist 
Circumfer
ence 
NMS Group 
(Only ACS)  
MS Group 
(ACS with 
Metabolic 
syndrome) 
P  
value 
Statistica
l test 
n Mean SD n 
Mea
n 
SD 
1 Overall 38 81.3 7.2 12 98.3 9.7 
<0.0001*
* 
Unpaired 
‘t’ test 
2 
Male 
gender 
29 82.4 7.1 9 98.7 11.26 
<0.0001*
* 
Unpaired 
‘t’ test 
3 
Female 
gender 
9 77.5 6.5 3 97 2.64 0.006* 
Unpaired 
‘t’ test 
 
Data are expressed as mean with standard deviation. * indicates p value <0.05 
which is considered highly significant. ** indicates p<0.0001 which is 
considered extremely significant. 
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Table 9: Comparison of clinical components of metabolic syndrome 
between the groups in the study population 
 
S. 
N
o 
Parameter 
NMS Group 
(Only ACS)  
(n=38) 
MS Group 
(ACS with 
Metabolic 
syndrome) (n=12) P  value 
Odds 
ratio  
(95% 
CI) 
n % n % 
1 
Elevated 
waist 
circumfere
nce 
Yes 5 13.1 12 100 
<0.0001
* 
152 
(7.8 to 
2962) No 33 86.8 0 0 
2 High BP 
Yes 14 36.8 7 58.3 
0.31 
(NS) -- 
No 24 63.1 5 41.7 
 
Fisher’s exact test was used to test the difference between the proportions. 
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Figure 3: Prevalence of clinical components of metabolic syndrome 
between the groups in the study population. (data are expressed as 
percentages). 
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Table 10: Comparison of biochemical components of metabolic syndrome 
between the groups in the study population 
 
S. 
N
o 
Parameter 
NMS Group 
(Only ACS)  
(n=38) 
MS Group 
(ACS with 
Metabolic 
syndrome) (n=12) P  value 
Odds 
ratio  
(95% CI) 
n % n % 
1 High TGs 
Yes 1 2.63 6 50 
0.0004* 
37 
(3.7 to 
364.1) No 37 97.3 6 50 
2 Elevated FBS 
Yes 6 15.7 6 50 
0.024* 
5.33 
(1.2 to 
22.2) No 32 84.2 6 50 
3 Low HDL 
Yes 16 42.1 8 66.7 
0.19 
(NS) --- 
No 22 57.8 4 33.3 
 
Fisher’s exact test was used to test the difference between the proportions. 
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Figure 4: Prevalence of biochemical components of metabolic syndrome in 
the groups of the study population 
 
 
 
Data are expressed as percentages. 
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RESULT: 
• The prevalence of MS was 76% (76.3% male and 75% female) 
• Most of patients found between 41 to 70 years age group. 
• Common presentation of ACS was STEMI (80%)followed by the 
NSTEMI (6%) and unstable angina (UA) (4%) . 
• In MS group of patients STEMI presentation was 83.3% followed by 
NSTEMI (8.3%) and UA (8.3%). 
• Fasting glucose was elevated to the extent of 50% in the metabolic 
syndrome group and it was statistically significant. 
• The total cholesterol were increased in both the groups and there was no 
significance in both the groups. 
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DISCUSSION. 
50 proven cases of acute coronary syndrome  who were admitted to the cardiac 
intensive care unit were selected for analyzing the prevalence of metabolic 
syndrome. All of them satisfied the inclusion criteria .All patients were 
subjected to  the detailed clinical history and examination. BP was recorded 
from all patients.12 lead ECG was done whenever indicated. ECHO was done 
for all patients. 
Abdominal circumference of all patients were measured in standing position at 
a point midway between lower most point of costal margin and upper most 
point of iliac crest. In a few moribund patients who could not stand, 
measurement was taken in supine position. 
Blood samples were taken for analysis of fasting blood sugar, urea, creatinine 
and electrolytes on the first day and for fasting blood sugar and lipid profile on 
the  morning of day 3. 
In our study the 12 patients who satisfied the criteria for metabolic syndrome 
were taken as study subjects and the remaining 38 patients who had no 
metabolic syndrome served as the control group. 
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Limitations of the study: 
• Few sample size. 
• NSTEMI was not confirmed by cardiac biomarkers. 
• Angiography was not included in the study. 
• Other tests like microalbuminuria, which is a part of WHO criteria for 
diagnosing metabolic syndrome and a good predictor for cardiovascular 
diseases were not studied.   
• Although the risk factors were assessed at the time of index event, the 
duration of risk factors before MI could not be assessed. Hb A1c was not 
studied.  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CONCLUSION 
 The prevalence of MS was 76% (76.3% male and 75% female) with 
IDF-criteria. Number of male patients was higher in  the above group. Our 
study not aimed at a particular population or age group, the bulk of patients 
found between 41 to 70 years age group. 
Out of these 50 patients we found the more common presentation of 
ACS was STEMI (80%)followed by the NSTEMI (6%) and unstable angina 
(UA) (4%) . There was no significant difference in prevalence of presenting 
symptoms. In MS group of patients STEMI presentation was 83.3% followed 
by NSTEMI (8.3%) and UA (8.3%). In NMS group STEMI was present in 
92.1% followed by the NSTEMI (5.3%) and UA (2.6%). 
Waist circumference of more than 90 cms in male and > 80 cms in 
female was prevalent in 100% of the metabolic syndrome group and it showed 
statistical significance (p=0.0001). 
Fasting glucose was elevated to the extent of 50% in the metabolic 
syndrome group and it was statistically significant (p= 0.024). 
Triglycerides was elevated to 50% in the metabolic syndrome group and 
this also showed to be statistically significant P <0.0004 
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The total cholesterol were increased in both the groups and there was no 
significance in both the groups. Though smoking and alcohol was more 
prevalent in the non-metabolic syndrome group this was not significant 
statistically. 
Among 50 patients studied for the prevalence of metabolic syndrome in 
patients with acute coronary syndrome the overall prevalence was 76% .  
Triglycerides and blood pressure and waist circumference highly 
influenced the occurrence of metabolic syndrome. Metabolic syndrome is 
associated with increased risk of devoleping  CVD So to prevent the 
complications due to metabolic syndrome there is a need for early and intensive 
preventive measures.  
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A1.PROFORMA 
 
Name  :   Age :   Sex : M/F 
Occupation :   IP :    wd : 
Diagnose : 
PAST H/O  : T2DM / SHT / CAD / CKD / PTB / BA / CVA 
PERSONAL H/O : SMOKER / ALCOHOLIC /DRUG ABUSE / DIET 
FAMILY H/O : CAD / CVA / FAMILIAL TRIGLYCIDIMIA  
O/E   : PATIENT 
    CONSIOUS 
    ORIENTED 
    TACHYPNOEIC 
    PALLOR / ICTERVS 
    CYANOSIS / CLUBBING 
    PEDAL OEDEMA 
CVS  : S1S2+ 
RS  : B/L VBS + 
P/A  : SOFT 
CNS  : NFND 
 
 
  
 
Criteria for Clinical Diagnosis of the Metabolic Syndrome 
 
WAIST CIRCUMFERENCE 
 
BLOOD PRESSURE 
 
FBS 
 
TG 
 
HDL – C  
 
ECG  : 
ECHO : 
 
 
 
 
                                                 
 
 
 
  
 
A2. CONSENT FORM 
     
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR . SANGEETHA.G ,Post graduate in 
the Department of  General Medicine ,Thanjavur Medical College & Hospital, 
Thanjavur – 613004 and to use my personal clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I also 
give consent for further investigations 
 
 
 
Place: 
Date  :                                                                            Signature of the participant  
  
ஒத ப வ	 
 
ெப ய : 
வய : 
ப ாலின	 : 
கவ: 
 
தசா அர ம வக  ம வம ைனயி 
நைடெப %	 இ'த ஆ)வி * ச	ம தட+ கல'ெகா,ள 
ச	ம திகிேற+  .இ'த ஆ)வி எ+ைன ப 1றி விவர2கைள 
ப ாகாட+ இ'த ஆ)வி  ெவளியிட ஆ4ேசப ைண இைல 
எ+% ெதவி ெகா,கிேற+  .எ'த ேநரதி6	 ஆ)வி 
இ' விலகிெகா,7	  உைம  உ9: எ+% அறிேவ+  . 
 
 
இட	 : 
ேததி: 
                                                                                                 ைகெகயாப 	  /ேரைக 
